Statement of Changes in Beneficial Ownership (4)
July 10 2020 - 1:26PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
Slilaty Steve N. |
2. Issuer Name and Ticker or Trading Symbol
Sunshine Biopharma, Inc
[
SBFM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Executive Officer |
|
(Last)
(First)
(Middle)
579 RUE LAJEUNESSE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/20/2019 |
|
(Street)
LAVAL, A8 H7X 3K4
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 10/20/2019 | | A | | 1100000 (1) | A | $0.001 | 2043461 (1) | D | |
| Common Stock | 12/19/2019 | | A | | 1300000 (1) | A | $0.001 | 3343461 (1) | D | |
| Common Stock | 12/31/2019 | | J(2) | | 323673 (1) | A | $0.001 | 861209 (1) | I | Held by TRT Pharma Inc., an entity controlled by the Reporting Person. (2) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | The amounts of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. |
| (2) | Effective December 31, 2019, Advanomics Corporation, a entity controlled by the Reporting Person, effectuated a consolidation with 4019318 Canada, Inc., an entity controlled by the Chief Financial Officer of the Issuer. The resulting consoildated entity changed its name to TRT Pharma Inc. The consolidation resulted in the transfer of 323,673 shares of post-reverse splits of the Issuer's Common Stock to TRT Pharma Inc. of which the Reporting Person is a control person. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
Slilaty Steve N.
579 RUE LAJEUNESSE
LAVAL, A8 H7X 3K4 | X |
| Chief Executive Officer |
|
Signatures
|
| Steve N. Slilaty | | 7/10/2020 |
| **Signature of Reporting Person | Date |